Evaluation of Psoriasis Area and Severity Index as a Proxy for Biomarkers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment Cycles
DOI:
https://doi.org/10.2340/00015555-3814Keywords:
psoriasis, biologics, biomarker, neutrophil-to-lymphocyte ratio, Psoriasis Area and Severity IndexAbstract
The efficacy of psoriasis treatments is usually evaluated using the Psoriasis Area and Severity Index (PASI). However, there is a lack of systematic statistical assessments of PASI as a proxy for systemic disease in individual patients. Therefore, a retrospective study of 186 treatments with adalimumab, etanercept, and ustekinumab for psoriasis (341 patient-years) was performed. While PASI significantly and independently correlated with biomarkers of systemic inflammation (especially neutrophil-to-lymphocyte ratio, C-reactive protein), the strengths were only weak-to-moderate and varied considerably inter-individually. A decrease in PASI indicated a neutrophil-to-lymphocyte ratio decrease and a C-reactive protein decrease or stable low margin C-reactive protein in ≥ 80%. Sensitivity, specificity, and positive predictive value of PASI 0 and PASI 2.75 (optimal Youden Index) for low cardiovascular risk C-reactive protein were 24%, 92%, 85%, and 62%, 61%, 76%, respectively. Performance was similar using absolute thresholds and PASI 100 or PASI 75, and overall worse for low cardiovascular risk neutrophil-to-lymphocyte ratio and if psoriasis arthritis was present. In conclusion, PASI allows robust low-order estimates of systemic inflammation, but cannot substitute for laboratory biomarkers for more precise assessments.
Downloads
References
Boehncke WH, Schon MP. Psoriasis. Lancet 2015; 386: 983-994.
DOI: https://doi.org/10.1016/S0140-6736(14)61909-7
Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am 2009; 29: 247-264.
DOI: https://doi.org/10.1016/j.iac.2009.02.002
Boehncke WH. systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol 2018; 9: 579.
DOI: https://doi.org/10.3389/fimmu.2018.00579
Gelfand JM. Commentary: does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality?: a critical question that we are only just beginning to answer. J Am Acad Dermatol 2018; 79: 69-70.
DOI: https://doi.org/10.1016/j.jaad.2018.03.046
Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br J Dermatol 2010; 163: 586-592.
DOI: https://doi.org/10.1111/j.1365-2133.2010.09941.x
Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol 2008; 159: 2-9.
DOI: https://doi.org/10.1111/j.1365-2133.2008.08779.x
Nast A, Spuls PI, van der Kraaij G, Gisondi P, Paul C, Ormerod AD, et al. European S3-guideline on the systemic treatment of psoriasis vulgaris - update apremilast and secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2017; 31: 1951-1963.
DOI: https://doi.org/10.1111/jdv.14454
Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol 2020; 182: 840-848.
DOI: https://doi.org/10.1111/bjd.18245
Beygi S, Lajevardi V, Abedini R. C-reactive protein in psoriasis: a review of the literature. J Eur Acad Dermatol Venereol 2014; 28: 700-711.
DOI: https://doi.org/10.1111/jdv.12257
Garcia-Martinez P, Collado-Diaz V, Mateu-Puchades A, Villarroel-Vicente C, Rovira-Llopis S, Blas-Garcia A, et al. Differential effects of biologics on psoriasis-related vascular inflammation and risk of thrombosis. J Invest Dermatol 2020; 140: 2294-2298.e6.
DOI: https://doi.org/10.1016/j.jid.2020.02.039
Mehta NN, Shin DB, Joshi AA, Dey AK, Armstrong AW, Duffin KC, et al. Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial. Circ Cardiovasc Imaging 2018; 11: e007394.
DOI: https://doi.org/10.1161/CIRCIMAGING.117.007394
Dey AK, Joshi AA, Chaturvedi A, Lerman JB, Aberra TM, Rodante JA, et al. Association between skin and aortic vascular inflammation in patients with psoriasis: a case-cohort study using positron emission tomography/computed tomography. JAMA Cardiol 2017; 2: 1013-1018.
DOI: https://doi.org/10.1001/jamacardio.2017.1213
Kim BS, Lee WK, Pak K, Han J, Kim GW, Kim HS, et al. Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study using (18)F-fluorodeoxyglucose PET/CT. J Am Acad Dermatol 2019; 80: 1322-1331.
DOI: https://doi.org/10.1016/j.jaad.2018.03.011
Bissonnette R, Harel F, Krueger JG, Guertin MC, Chabot-Blanchet M, Gonzalez J, et al. TNF-alpha antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study. J Invest Dermatol 2017; 137: 1638-1645.
DOI: https://doi.org/10.1016/j.jid.2017.02.977
Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris Update 2011. J Dtsch Dermatol Ges 2011; 9: S1-104.
DOI: https://doi.org/10.1111/j.1610-0379.2011.07680.x
Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39: 175-191.
DOI: https://doi.org/10.3758/BF03193146
Cohen J. Statistical power analysis for the behavioral sciences. 2nd edn. Hillsdale, NJ: L. Erlbaum Associates, 1988.
Kim S, Eliot M, Koestler DC, Wu WC, Kelsey KT. Association of neutrophil-to-lymphocyte ratio with mortality and cardiovascular disease in the Jackson heart study and modification by the duffy antigen variant. JAMA Cardiol 2018; 3: 455-462.
DOI: https://doi.org/10.1001/jamacardio.2018.1042
Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.
DOI: https://doi.org/10.1161/01.CIR.0000053730.47739.3C
Hoffmann JH, Knoop C, Enk AH, Hadaschik EN. Routine laboratory parameter dynamics and laboratory adverse events in psoriasis patients on long-term treatment with adalimumab, etanercept, and ustekinumab. Acta Derm Venereol 2017; 97: 705-710.
DOI: https://doi.org/10.2340/00015555-2644
Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008; 159: 322-330.
DOI: https://doi.org/10.1111/j.1365-2133.2008.08628.x
Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol 2010; 24: 789-796.
DOI: https://doi.org/10.1111/j.1468-3083.2009.03527.x
Strober BE, Poulin Y, Teller C, Wang Y, Williams DA, Goldblum OM. Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy. J Eur Acad Dermatol Venereol 2014; 28: 1701-1706.
DOI: https://doi.org/10.1111/jdv.12372
Boehncke S, Salgo R, Garbaraviciene J, Beschmann H, Hardt K, Diehl S, et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2011; 25: 1187-1193.
DOI: https://doi.org/10.1111/j.1468-3083.2010.03947.x
Montaudie H, Albert-Sabonnadiere C, Acquacalda E, Fontas E, Danre A, Roux C, et al. Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2014; 28: 1186-1191.
DOI: https://doi.org/10.1111/jdv.12255
Paliogiannis P, Satta R, Deligia G, Farina G, Bassu S, Mangoni AA, et al. Associations between the neutrophil-to-lymphocyte and the platelet-to-lymphocyte ratios and the presence and severity of psoriasis: a systematic review and meta-analysis. Clin Exp Med 2019; 19: 37-45.
DOI: https://doi.org/10.1007/s10238-018-0538-x
Asahina A, Kubo N, Umezawa Y, Honda H, Yanaba K, Nakagawa H. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: response to therapy with biologics. J Dermatol 2017; 44: 1112-1121.
DOI: https://doi.org/10.1111/1346-8138.13875
Zhang L, Wiles C, Martinez LR, Han G. Neutrophil-to-lymphocyte ratio decreases after treatment of psoriasis with therapeutic antibodies. J Eur Acad Dermatol Venereol 2017; 31: e491-e492.
DOI: https://doi.org/10.1111/jdv.14334
Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006; 113: 2335-2362.
DOI: https://doi.org/10.1161/CIRCULATIONAHA.104.482570
Wang J, Tan GJ, Han LN, Bai YY, He M, Liu HB. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol 2017; 14: 135-150.
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 140: e596-e646.
DOI: https://doi.org/10.1161/CIR.0000000000000725
Gelfand JM, Shin DB, Alavi A, Torigian DA, Werner T, Papadopoulos M, et al. A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U Trial). J Invest Dermatol 2020; 140: 85-93.e2.
DOI: https://doi.org/10.1016/j.jid.2019.07.679
von Stebut E, Reich K, Thaci D, Koenig W, Pinter A, Korber A, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol 2019; 139: 1054-1062.
DOI: https://doi.org/10.1016/j.jid.2018.10.042
Augustin M, Spehr C, Radtke MA, Boehncke WH, Luger T, Mrowietz U, et al. German psoriasis registry PsoBest: objectives, methodology and baseline data. J Dtsch Dermatol Ges 2014; 12: 48-57.
Additional Files
Published
How to Cite
License
Copyright (c) 2021 Jochen H.O. Hoffmann, Christian Knoop, Knut Schäkel, Alexander H. Enk, Eva N. Hadaschik
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
